{"id":"tinzaparin-continuous-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL1201414","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tinzaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of thrombin (factor IIa) and factor Xa. This prevents thrombus formation and propagation. When administered as a continuous infusion, it provides sustained anticoagulation for thromboembolism prevention and treatment.","oneSentence":"Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:45.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism (VTE) treatment and prevention"},{"name":"Deep vein thrombosis (DVT) treatment"},{"name":"Pulmonary embolism (PE) treatment"}]},"trialDetails":[{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT06712004","phase":"PHASE2","title":"A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-02-10","conditions":"Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction","enrollment":40},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT05540834","phase":"PHASE2","title":"Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","status":"RECRUITING","sponsor":"South West Sydney Local Health District","startDate":"2022-05-18","conditions":"Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown","enrollment":70},{"nctId":"NCT03614741","phase":"PHASE4","title":"Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients","status":"UNKNOWN","sponsor":"Tampere University Hospital","startDate":"2018-12-03","conditions":"Acute Kidney Injury, Renal Replacement Therapy, Anticoagulants","enrollment":60},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT02474212","phase":"PHASE4","title":": Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2016-05","conditions":"Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis","enrollment":85},{"nctId":"NCT02923115","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-06-23","conditions":"Pulmonary Embolism, Thrombotic Disease","enrollment":134},{"nctId":"NCT05493163","phase":"PHASE4","title":"Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism","status":"RECRUITING","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2022-10-19","conditions":"Pulmonary Embolism","enrollment":558},{"nctId":"NCT04475588","phase":"PHASE2","title":"Efficacy and Safety of Itolizumab in COVID-19 Complications","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2020-05-01","conditions":"Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19","enrollment":32},{"nctId":"NCT04528888","phase":"PHASE3","title":"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection","status":"UNKNOWN","sponsor":"Massimo Girardis","startDate":"2020-11-25","conditions":"Covid19, SARS-CoV Infection, Pneumonia, Viral","enrollment":210},{"nctId":"NCT04829552","phase":"","title":"Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2020-03-10","conditions":"Covid19","enrollment":704},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT01839487","phase":"PHASE2","title":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-05-14","conditions":"Metastatic Pancreatic Cancer","enrollment":279},{"nctId":"NCT04121611","phase":"NA","title":"Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-10-14","conditions":"Stroke of Basilar Artery, Optical Coherence Tomography, Antithrombotics","enrollment":25},{"nctId":"NCT00986154","phase":"PHASE3","title":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-10","conditions":"Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":8292},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT02095509","phase":"PHASE4","title":"Pharmacokinetics of Enoxaparin in Intensive Care Patients","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2014-03","conditions":"Venous Thromboembolism","enrollment":39},{"nctId":"NCT01532544","phase":"PHASE2","title":"Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis","status":"TERMINATED","sponsor":"Thrombologic ApS","startDate":"2012-06","conditions":"Pneumonia","enrollment":5},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT01648036","phase":"PHASE2","title":"Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2012-07","conditions":"Septic Shock","enrollment":76},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02159287","phase":"PHASE2","title":"Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2014-01","conditions":"Embolic Stroke","enrollment":80},{"nctId":"NCT00323011","phase":"PHASE2","title":"FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-05","conditions":"Colorectal Cancer","enrollment":5},{"nctId":"NCT01626911","phase":"NA","title":"Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis","status":"UNKNOWN","sponsor":"Nanjing University School of Medicine","startDate":"2011-09","conditions":"Acute Pancreatitis","enrollment":60},{"nctId":"NCT00916669","phase":"PHASE2","title":"A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00113932","phase":"PHASE2","title":"UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT00796692","phase":"PHASE4","title":"Nadroparin for the Initial Treatment of Pulmonary Thromboembolism","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":"Pulmonary Embolism, Thromboembolism, Vascular Diseases","enrollment":274},{"nctId":"NCT00628576","phase":"PHASE3","title":"Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"1993-10","conditions":"Deep Venous Thrombosis","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tinzaparin continuous infusion","genericName":"Tinzaparin continuous infusion","companyName":"Tampere University Hospital","companyId":"tampere-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tinzaparin is an oligosaccharide antithrombin-III activator used to treat conditions such as Deep Vein Thrombosis. It is administered via continuous infusion, although specific dosing and treatment protocols may vary depending on the condition being treated.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}